Table 1.
Global patient characteristics and by treatment.
| Global Group (N = 405) |
R-CHOP (N = 245) |
R-BENDA (N = 160) |
p | |
|---|---|---|---|---|
| Median months from biopsy to initial treatment median (range) | 0.90 (0–144) | 0.73 (0–144) | 1.30 (0–66) | <0.001 |
| Median age at first line (range) | 59 (21–100) | 57 (21–83) | 62 (30–100) | 0.003 |
| Sex Male Female Missing |
201 (50%) 202 (50%) 2 |
125 (51%) 119 (49%) |
76 (48%) 83 (52%) |
0.54 |
| Age (years) ≤60 >60 Missing |
208 (52%) 188 (47%) 9 |
138 (56%) 107 (44%) |
70 (46%) 81 (54%) |
0.062 |
| Ann Arbor stage I-II bulky III-IV Missing |
31 (8%) 361 (92%) 13 |
20 (8%) 219 (92%) |
11 (7%) 142 (93%) |
0.71 |
| B symptoms present No Yes Missing |
242 (64%) 136 (35%) 27 |
154 (65%) 81 (34%) |
88 (61%) 55 (38%) |
0.44 |
| ECOG performance status 0–1 2–4 Missing |
307 (93%) 23 (7%) 75 |
186 (92%) 16 (8%) |
121 (94%) 7 (5%) |
0.51 |
| Bone marrow involvement No Yes Missing |
198 (50%) 195 (50%) 12 |
128 (53%) 115 (47%) |
70 (47%) 80 (53%) |
0.25 |
| FLIPI score 0–1 2 3–5 Missing |
66 (17) 145 (38) 171 (45) 23 |
39 (17%) 78 (33%) 118 (50%) |
27 (18%) 67 (46%) 53 (36%) |
0.020 |
| Histological grade 1 2 3a Missing |
145 (39) 151 (41) 75 (20) 34 |
82 (36%) 85 (37%) 60 (26%) |
63 (44%) 66 (46%) 15 (10%) |
<0.001 |
| Induction regimen R-CHOP R-Bendamustine |
245 (60) 160 (40) |
--- | --- | --- |
| Rituximab maintenance: Yes No |
392 (97%) 13 (3%) |
237 (97%) 8 (3%) |
155 (97%) 5 (3%) |
1 |